Long-term hepatitis B virus (HBV) response to Lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand

• Main Authors: Woottichai Khamduang, Catherine Gaudy-Graffin, Nicole Ngo-Giang-Huong, Gonzague Jourdain, Alain Moreau, Nuananong Luekamlung, Guttiga Halue, Yuwadee Buranawanitchakorn, Sura Kunkongkapan, Sudanee Buranabanjasatean, Marc Lallemant, Wasna Sirirungsi, Alain Goudeau
• Format: Journal
• Published: 2018
• Subjects: Agricultural and Biological Sciences; Biochemistry, Genetics and Molecular Biology; Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84864447642&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/51266
• Institution: Chiang Mai University

Background: Approximately 4 million of people are co-infected with HIV and Hepatitis B virus (HBV). In resource-limited settings, the majority of HIV-infected patients initiate first-line highly active antiretroviral therapy containing lamivudine (3TC-containing-HAART) and long-term virological resp...